JP2006507363A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006507363A5 JP2006507363A5 JP2005501800A JP2005501800A JP2006507363A5 JP 2006507363 A5 JP2006507363 A5 JP 2006507363A5 JP 2005501800 A JP2005501800 A JP 2005501800A JP 2005501800 A JP2005501800 A JP 2005501800A JP 2006507363 A5 JP2006507363 A5 JP 2006507363A5
- Authority
- JP
- Japan
- Prior art keywords
- dichlorophenyl
- piperidine
- methyl
- cis
- trans
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002193 Pain Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 208000017194 Affective disease Diseases 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 4
- 208000019022 Mood disease Diseases 0.000 claims description 4
- 208000008548 Tension-Type Headache Diseases 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 208000019906 panic disease Diseases 0.000 claims description 4
- 208000007848 Alcoholism Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010012335 Dependence Diseases 0.000 claims description 3
- 206010046543 Urinary incontinence Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 206010013663 drug dependence Diseases 0.000 claims description 3
- 208000024714 major depressive disease Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 208000011117 substance-related disease Diseases 0.000 claims description 3
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 2
- 206010003805 Autism Diseases 0.000 claims description 2
- 208000020706 Autistic disease Diseases 0.000 claims description 2
- 208000008035 Back Pain Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 208000032841 Bulimia Diseases 0.000 claims description 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 2
- 206010058019 Cancer Pain Diseases 0.000 claims description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
- 208000026097 Factitious disease Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 206010065390 Inflammatory pain Diseases 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 208000000112 Myalgia Diseases 0.000 claims description 2
- 241000208125 Nicotiana Species 0.000 claims description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 2
- 206010057852 Nicotine dependence Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000004983 Phantom Limb Diseases 0.000 claims description 2
- 206010056238 Phantom pain Diseases 0.000 claims description 2
- 208000008348 Post-Concussion Syndrome Diseases 0.000 claims description 2
- 208000004550 Postoperative Pain Diseases 0.000 claims description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 2
- 206010052276 Pseudodementia Diseases 0.000 claims description 2
- 206010041250 Social phobia Diseases 0.000 claims description 2
- 208000025569 Tobacco Use disease Diseases 0.000 claims description 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 2
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims description 2
- 208000026345 acute stress disease Diseases 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 2
- 208000025748 atypical depressive disease Diseases 0.000 claims description 2
- 208000029028 brain injury Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 210000001097 facial muscle Anatomy 0.000 claims description 2
- 201000001881 impotence Diseases 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 208000013465 muscle pain Diseases 0.000 claims description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 2
- 206010036596 premature ejaculation Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 230000002889 sympathetic effect Effects 0.000 claims description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- JSFLWYCGKXACCB-STQMWFEESA-N (3s,4r)-4-(3,4-dichlorophenyl)-3-(ethoxymethyl)-1-methylpiperidine Chemical compound CCOC[C@@H]1CN(C)CC[C@H]1C1=CC=C(Cl)C(Cl)=C1 JSFLWYCGKXACCB-STQMWFEESA-N 0.000 claims 3
- XXIJUHUWXBINFK-RYUDHWBXSA-N (3s,4r)-4-(3,4-dichlorophenyl)-3-(methoxymethyl)-1-methylpiperidine Chemical compound COC[C@@H]1CN(C)CC[C@H]1C1=CC=C(Cl)C(Cl)=C1 XXIJUHUWXBINFK-RYUDHWBXSA-N 0.000 claims 3
- JSFLWYCGKXACCB-QWHCGFSZSA-N (3s,4s)-4-(3,4-dichlorophenyl)-3-(ethoxymethyl)-1-methylpiperidine Chemical compound CCOC[C@@H]1CN(C)CC[C@@H]1C1=CC=C(Cl)C(Cl)=C1 JSFLWYCGKXACCB-QWHCGFSZSA-N 0.000 claims 3
- XXIJUHUWXBINFK-NWDGAFQWSA-N (3s,4s)-4-(3,4-dichlorophenyl)-3-(methoxymethyl)-1-methylpiperidine Chemical compound COC[C@@H]1CN(C)CC[C@@H]1C1=CC=C(Cl)C(Cl)=C1 XXIJUHUWXBINFK-NWDGAFQWSA-N 0.000 claims 3
- MJXCQNLPSHLHLI-GJZGRUSLSA-N (3s,4r)-3-(cyclopropylmethoxymethyl)-4-(3,4-dichlorophenyl)-1-methylpiperidine Chemical compound C([C@H]1[C@@H](CCN(C1)C)C=1C=C(Cl)C(Cl)=CC=1)OCC1CC1 MJXCQNLPSHLHLI-GJZGRUSLSA-N 0.000 claims 2
- SBMHBPNXTZWHHN-KBPBESRZSA-N (3s,4r)-3-(cyclopropylmethoxymethyl)-4-(3,4-dichlorophenyl)piperidine Chemical compound C1=C(Cl)C(Cl)=CC=C1[C@H]1[C@H](COCC2CC2)CNCC1 SBMHBPNXTZWHHN-KBPBESRZSA-N 0.000 claims 2
- VUQRPUBTPUWZTD-GJZGRUSLSA-N (3s,4r)-4-(3,4-dichlorophenyl)-1-methyl-3-(2-methylpropoxymethyl)piperidine Chemical compound CC(C)COC[C@@H]1CN(C)CC[C@H]1C1=CC=C(Cl)C(Cl)=C1 VUQRPUBTPUWZTD-GJZGRUSLSA-N 0.000 claims 2
- JGKLOYNZPIFDON-KBPBESRZSA-N (3s,4r)-4-(3,4-dichlorophenyl)-3-(2-methylpropoxymethyl)piperidine Chemical compound CC(C)COC[C@@H]1CNCC[C@H]1C1=CC=C(Cl)C(Cl)=C1 JGKLOYNZPIFDON-KBPBESRZSA-N 0.000 claims 2
- GNCAUTYULVCEJZ-RYUDHWBXSA-N (3s,4r)-4-(3,4-dichlorophenyl)-3-(ethoxymethyl)piperidine Chemical compound CCOC[C@@H]1CNCC[C@H]1C1=CC=C(Cl)C(Cl)=C1 GNCAUTYULVCEJZ-RYUDHWBXSA-N 0.000 claims 2
- UAJKBUYVPSQOSC-QWRGUYRKSA-N (3s,4r)-4-(3,4-dichlorophenyl)-3-(methoxymethyl)piperidine Chemical compound COC[C@@H]1CNCC[C@H]1C1=CC=C(Cl)C(Cl)=C1 UAJKBUYVPSQOSC-QWRGUYRKSA-N 0.000 claims 2
- MJXCQNLPSHLHLI-LSDHHAIUSA-N (3s,4s)-3-(cyclopropylmethoxymethyl)-4-(3,4-dichlorophenyl)-1-methylpiperidine Chemical compound C([C@H]1[C@H](CCN(C1)C)C=1C=C(Cl)C(Cl)=CC=1)OCC1CC1 MJXCQNLPSHLHLI-LSDHHAIUSA-N 0.000 claims 2
- SBMHBPNXTZWHHN-UONOGXRCSA-N (3s,4s)-3-(cyclopropylmethoxymethyl)-4-(3,4-dichlorophenyl)piperidine Chemical compound C1=C(Cl)C(Cl)=CC=C1[C@@H]1[C@H](COCC2CC2)CNCC1 SBMHBPNXTZWHHN-UONOGXRCSA-N 0.000 claims 2
- VUQRPUBTPUWZTD-LSDHHAIUSA-N (3s,4s)-4-(3,4-dichlorophenyl)-1-methyl-3-(2-methylpropoxymethyl)piperidine Chemical compound CC(C)COC[C@@H]1CN(C)CC[C@@H]1C1=CC=C(Cl)C(Cl)=C1 VUQRPUBTPUWZTD-LSDHHAIUSA-N 0.000 claims 2
- JGKLOYNZPIFDON-UONOGXRCSA-N (3s,4s)-4-(3,4-dichlorophenyl)-3-(2-methylpropoxymethyl)piperidine Chemical compound CC(C)COC[C@@H]1CNCC[C@@H]1C1=CC=C(Cl)C(Cl)=C1 JGKLOYNZPIFDON-UONOGXRCSA-N 0.000 claims 2
- GNCAUTYULVCEJZ-NWDGAFQWSA-N (3s,4s)-4-(3,4-dichlorophenyl)-3-(ethoxymethyl)piperidine Chemical compound CCOC[C@@H]1CNCC[C@@H]1C1=CC=C(Cl)C(Cl)=C1 GNCAUTYULVCEJZ-NWDGAFQWSA-N 0.000 claims 2
- UAJKBUYVPSQOSC-WDEREUQCSA-N (3s,4s)-4-(3,4-dichlorophenyl)-3-(methoxymethyl)piperidine Chemical compound COC[C@@H]1CNCC[C@@H]1C1=CC=C(Cl)C(Cl)=C1 UAJKBUYVPSQOSC-WDEREUQCSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 206010043269 Tension headache Diseases 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- MJXCQNLPSHLHLI-UHFFFAOYSA-N 3-(cyclopropylmethoxymethyl)-4-(3,4-dichlorophenyl)-1-methylpiperidine Chemical compound C1N(C)CCC(C=2C=C(Cl)C(Cl)=CC=2)C1COCC1CC1 MJXCQNLPSHLHLI-UHFFFAOYSA-N 0.000 claims 1
- SBMHBPNXTZWHHN-UHFFFAOYSA-N 3-(cyclopropylmethoxymethyl)-4-(3,4-dichlorophenyl)piperidine Chemical compound C1=C(Cl)C(Cl)=CC=C1C1C(COCC2CC2)CNCC1 SBMHBPNXTZWHHN-UHFFFAOYSA-N 0.000 claims 1
- VUQRPUBTPUWZTD-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-1-methyl-3-(2-methylpropoxymethyl)piperidine Chemical compound CC(C)COCC1CN(C)CCC1C1=CC=C(Cl)C(Cl)=C1 VUQRPUBTPUWZTD-UHFFFAOYSA-N 0.000 claims 1
- JSFLWYCGKXACCB-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-3-(ethoxymethyl)-1-methylpiperidine Chemical compound CCOCC1CN(C)CCC1C1=CC=C(Cl)C(Cl)=C1 JSFLWYCGKXACCB-UHFFFAOYSA-N 0.000 claims 1
- GNCAUTYULVCEJZ-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-3-(ethoxymethyl)piperidine Chemical compound CCOCC1CNCCC1C1=CC=C(Cl)C(Cl)=C1 GNCAUTYULVCEJZ-UHFFFAOYSA-N 0.000 claims 1
- XXIJUHUWXBINFK-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-3-(methoxymethyl)-1-methylpiperidine Chemical compound COCC1CN(C)CCC1C1=CC=C(Cl)C(Cl)=C1 XXIJUHUWXBINFK-UHFFFAOYSA-N 0.000 claims 1
- UAJKBUYVPSQOSC-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-3-(methoxymethyl)piperidine Chemical compound COCC1CNCCC1C1=CC=C(Cl)C(Cl)=C1 UAJKBUYVPSQOSC-UHFFFAOYSA-N 0.000 claims 1
- 208000022497 Cocaine-Related disease Diseases 0.000 claims 1
- 208000008967 Enuresis Diseases 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010028403 Mutism Diseases 0.000 claims 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000006931 brain damage Effects 0.000 claims 1
- 231100000874 brain damage Toxicity 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 150000001805 chlorine compounds Chemical group 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 201000006145 cocaine dependence Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000029849 luteinization Effects 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000001256 tonic effect Effects 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 208000002271 trichotillomania Diseases 0.000 claims 1
- 206010046494 urge incontinence Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010016059 Facial pain Diseases 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 206010052794 Panic disorder with agoraphobia Diseases 0.000 description 1
- 206010033668 Panic disorder without agoraphobia Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 206010070606 Post stroke depression Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010040981 Sleep attacks Diseases 0.000 description 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000022257 bipolar II disease Diseases 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 230000000938 luteal effect Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 230000007074 memory dysfunction Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200201689 | 2002-11-01 | ||
| US46981703P | 2003-05-13 | 2003-05-13 | |
| DKPA200300727 | 2003-05-13 | ||
| PCT/DK2003/000734 WO2004039778A1 (en) | 2002-11-01 | 2003-10-30 | Novel piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006507363A JP2006507363A (ja) | 2006-03-02 |
| JP2006507363A5 true JP2006507363A5 (enExample) | 2010-09-16 |
Family
ID=32233825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005501800A Pending JP2006507363A (ja) | 2002-11-01 | 2003-10-30 | 新規ピペリジン誘導体及びこれをモノアミン神経伝達物質再取り込み阻害薬として使用する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7560562B2 (enExample) |
| EP (1) | EP1560813B1 (enExample) |
| JP (1) | JP2006507363A (enExample) |
| AT (1) | ATE461174T1 (enExample) |
| AU (1) | AU2003277827A1 (enExample) |
| BR (1) | BR0314821A (enExample) |
| CA (1) | CA2502704A1 (enExample) |
| DE (1) | DE60331762D1 (enExample) |
| PL (1) | PL375163A1 (enExample) |
| WO (1) | WO2004039778A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008502651A (ja) | 2004-06-18 | 2008-01-31 | ノイロサーチ アクティーゼルスカブ | モノアミン神経伝達物質再取込み阻害剤としての、新規アルキル置換ピペリジン誘導体及びその使用 |
| US7923444B2 (en) | 2005-02-10 | 2011-04-12 | Neurosearch A/S | Alkyl substituted homopiperazine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| US20090124663A1 (en) * | 2005-06-08 | 2009-05-14 | Neurosearch A/S | Novel n-phenyl-piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| JP2010501624A (ja) * | 2006-08-30 | 2010-01-21 | ノイロサーチ アクティーゼルスカブ | 新規なピペリジン誘導体及びモノアミン神経伝達物質再取込み阻害剤としてのその使用 |
| WO2010130672A1 (en) * | 2009-05-12 | 2010-11-18 | Glaxo Group Limited | Azabicyclo [4.1.0] heptane derivatives and their use as monoamine reuptake inhibitors |
| WO2014011768A1 (en) * | 2012-07-10 | 2014-01-16 | Adispell, Inc. | Anti-anxiety treatment |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1422263A (en) * | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
| US4485109A (en) * | 1982-05-07 | 1984-11-27 | E. I. Du Pont De Nemours And Company | 4-Aryl-4-piperidinecarbinols |
| EP0190496A3 (en) * | 1984-12-13 | 1987-05-27 | Beecham Group Plc | Piperidine derivatives having a gastro-intestinal activity |
| BR9707636A (pt) | 1996-02-22 | 1999-07-27 | Neurosearch As | Composto composição farmacêutica uso de um composto e processos para preparar composto e para tratar um distúrbio ou doença de um organismo animal vivo |
| AU744259B2 (en) * | 1997-04-07 | 2002-02-21 | Gian Luca Araldi | Analogs of cocaine |
| AU7206398A (en) * | 1997-05-14 | 1998-12-08 | Neurosearch A/S | Piperidine derivatives as neurotransmitter re-uptake inhibitors |
| US6440996B1 (en) * | 1998-10-07 | 2002-08-27 | Georgetown University | Monomeric and dimeric heterocycles, and therapeutic uses thereof |
-
2003
- 2003-10-30 AU AU2003277827A patent/AU2003277827A1/en not_active Abandoned
- 2003-10-30 EP EP03769250A patent/EP1560813B1/en not_active Expired - Lifetime
- 2003-10-30 JP JP2005501800A patent/JP2006507363A/ja active Pending
- 2003-10-30 PL PL03375163A patent/PL375163A1/xx unknown
- 2003-10-30 US US10/530,012 patent/US7560562B2/en not_active Expired - Fee Related
- 2003-10-30 AT AT03769250T patent/ATE461174T1/de not_active IP Right Cessation
- 2003-10-30 DE DE60331762T patent/DE60331762D1/de not_active Expired - Lifetime
- 2003-10-30 CA CA002502704A patent/CA2502704A1/en not_active Abandoned
- 2003-10-30 WO PCT/DK2003/000734 patent/WO2004039778A1/en not_active Ceased
- 2003-10-30 BR BR0314821-1A patent/BR0314821A/pt not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010513392A5 (enExample) | ||
| JP2010520265A5 (enExample) | ||
| JP2006507363A5 (enExample) | ||
| JP2009526816A5 (enExample) | ||
| JP2007520539A5 (enExample) | ||
| JP2008501758A5 (enExample) | ||
| AU2007251663B2 (en) | 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions | |
| JP2006517567A5 (enExample) | ||
| RU2005138591A (ru) | Новые производные 8-аза-бицикло{3.2.1}октана и их применение в качестве ингибиторов обратного захвата моноаминовых нейротрансмиттеров | |
| JP2009537599A5 (enExample) | ||
| RU2008129865A (ru) | Новые производные хромен-2-она и их применение в качестве ингибиторов обратного захвата нейромедиаторов моноаминов | |
| JP2006517568A5 (enExample) | ||
| JP2010513391A5 (enExample) | ||
| JP2008524161A5 (enExample) | ||
| BR0209343A (pt) | Antidepressivos de azaheterociclilmetila derivados de [1,4]-benzodioxanos oxaheterociclo-fundidos; métodos de tratamento usando tais compostos; processo para prepará-los | |
| JP2009526023A5 (enExample) | ||
| JP2008502650A5 (enExample) | ||
| JP2007523206A5 (enExample) | ||
| BR0209342A (pt) | Antidepressivos de azaheterociclilmetila derivados de 2,3 dihidro-1,4-dioxino[2,3-f]quinoxalina; método de tratamento usando tais compostos; processo para prepará-los | |
| JP2008502652A5 (enExample) | ||
| JP2008510775A5 (enExample) | ||
| JP2009537598A5 (enExample) | ||
| RU2005141065A (ru) | 2-метоксиметил-3-(3, 4-дихлорфенил)-8-азабицикло[3.2.1.]октана тартратные соли | |
| JP2005524712A5 (enExample) | ||
| JP2008510776A5 (enExample) |